An alternate explanation would be that the observed infiltrating MHC class II-expressing B cells would present shed tumor antigens to the vaccine-induced anti-HER-2 CD4pos Th1 cells, and these in turn would produce a soluble factor(s) that could diffuse into the tumor bed and mediate the observed biological effects on the tumor cells. The gene discussed is ERBB2; the disease is neoplasm.